Seres Therapeutics, Inc. (MCRB) DCF Valuation

Seres Therapeutics, Inc. (MCRB) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Seres Therapeutics, Inc. (MCRB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify Seres Therapeutics, Inc. (MCRB) valuation with this customizable DCF Calculator! Featuring real Seres Therapeutics, Inc. (MCRB) financials and adjustable forecast inputs, you can test scenarios and uncover Seres Therapeutics, Inc. (MCRB) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 34.5 33.2 144.9 7.1 126.3 158.3 198.3 248.5 311.3 390.1
Revenue Growth, % 0 -3.74 336.33 -95.08 1672.24 25.29 25.29 25.29 25.29 25.29
EBITDA -59.9 -77.3 -56.7 -237.5 -85.4 -128.8 -161.3 -202.1 -253.3 -317.3
EBITDA, % -173.73 -232.76 -39.14 -3332.04 -67.63 -81.35 -81.35 -81.35 -81.35 -81.35
Depreciation 9.8 8.9 9.2 11.9 6.2 52.7 66.1 82.8 103.7 130.0
Depreciation, % 28.49 26.77 6.36 166.29 4.94 33.31 33.31 33.31 33.31 33.31
EBIT -69.8 -86.2 -65.9 -249.4 -91.7 -132.3 -165.8 -207.8 -260.3 -326.2
EBIT, % -202.22 -259.53 -45.5 -3498.33 -72.57 -83.61 -83.61 -83.61 -83.61 -83.61
Total Cash 94.8 253.6 290.7 181.3 128.0 158.3 198.3 248.5 311.3 390.1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 1.8 9.4 .0 .0 8.7
Account Receivables, % 5.17 28.26 0 0 6.87
Inventories -29.7 .0 .0 .0 29.6 -19.8 -24.8 -31.1 -39.0 -48.8
Inventories, % -86.05 0.000003010688 0 0 23.47 -12.52 -12.52 -12.52 -12.52 -12.52
Accounts Payable 4.9 4.0 13.7 17.4 3.6 43.9 54.9 68.8 86.3 108.1
Accounts Payable, % 14.08 12.1 9.48 244.67 2.88 27.71 27.71 27.71 27.71 27.71
Capital Expenditure -1.0 -.6 -9.6 -9.8 -8.0 -37.2 -46.6 -58.4 -73.2 -91.7
Capital Expenditure, % -2.9 -1.78 -6.6 -137.78 -6.31 -23.52 -23.52 -23.52 -23.52 -23.52
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -63.8 -83.6 -61.8 -253.0 -91.7 -127.6 -159.9 -200.4 -251.0 -314.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.2 -113.4 -43.1 -247.3 -145.5 -26.5 -127.6 -159.9 -200.3 -251.0
WACC, % 8.58 8.8 8.67 8.92 8.92 8.78 8.78 8.78 8.78 8.78
PV UFCF
SUM PV UFCF -564.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -256
Terminal Value -3,778
Present Terminal Value -2,481
Enterprise Value -3,045
Net Debt 86
Equity Value -3,131
Diluted Shares Outstanding, MM 128
Equity Value Per Share -24.46

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
  • Real-World Data: Seres Therapeutics, Inc. (MCRB) financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model tailored to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • 🔍 Real-Life MCRB Financials: Pre-filled historical and projected data for Seres Therapeutics, Inc.
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Seres Therapeutics' intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Seres Therapeutics' valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Seres Therapeutics, Inc.'s (MCRB) preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures to fit your analysis.
  • 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV based on your inputs.
  • 4. Explore Different Scenarios: Evaluate various forecasts to understand the impact on valuation outcomes.
  • 5. Present with Assurance: Deliver professional valuation insights to bolster your decision-making process.

Why Choose This Calculator for Seres Therapeutics, Inc. (MCRB)?

  • Accuracy: Utilizes real Seres Therapeutics financial data for precise calculations.
  • Flexibility: Allows users to easily test and adjust inputs to fit their needs.
  • Time-Saving: Eliminate the complexities of creating a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and usability expected by top financial professionals.
  • User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling knowledge.

Who Should Use This Product?

  • Individual Investors: Gain insights for making informed decisions about investing in Seres Therapeutics, Inc. (MCRB).
  • Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for Seres Therapeutics, Inc. (MCRB).
  • Consultants: Provide clients with expert valuation analysis related to Seres Therapeutics, Inc. (MCRB) efficiently and effectively.
  • Business Owners: Learn from the valuation strategies of biotech companies like Seres Therapeutics, Inc. (MCRB) to inform your own business approaches.
  • Finance Students: Explore real-world valuation techniques through case studies involving Seres Therapeutics, Inc. (MCRB).

What the Template Contains

  • Preloaded MCRB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.